Stockscreener 앱 받기
4.91
2.58%
-0.13
시간 외 거래:
5.00
0.09
+1.83%
Candel Therapeutics Inc 주식(CADL)의 최신 뉴스
Paul Manning holds 7.9% of Candel Therapeutics (NASDAQ: CADL) shares - Stock Titan
Buy Signal: Should I hold or sell Candel Therapeutics Inc nowQuarterly Investment Review & Safe Capital Investment Plans - baoquankhu1.vn
H.C. Wainwright reiterates Candel stock rating on lung cancer data By Investing.com - Investing.com South Africa
Will Candel Therapeutics Inc outperform small cap indexesWall Street Watch & Weekly High Conviction Trade Ideas - baoquankhu1.vn
H.C. Wainwright reiterates Candel stock rating on lung cancer data - Investing.com
Candel Therapeutics, Inc. (NASDAQ:CADL) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Market movers: Uber, Getty Images, Candel Therapeutics... - Proactive Investors
Candel Therapeutics reports extended survival in Phase 2a lung cancer trial of CAN-2409 - Proactive financial news
Candel reports extended survival data for lung cancer therapy - Investing.com
Candel Therapeutics Inc extended survival tail observed in trial of aglatimagene besadenovec - marketscreener.com
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors - Bitget
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (Can-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors - marketscreener.com
Aug Drivers: Is Candel Therapeutics Inc stock forming a triangle pattern2026 Snapshot & Weekly High Return Opportunities - baoquankhu1.vn
FY2030 Earnings Forecast for CADL Issued By HC Wainwright - MarketBeat
Short Interest in Candel Therapeutics, Inc. (NASDAQ:CADL) Grows By 39.7% - MarketBeat
Analysts Have Conflicting Sentiments on These Healthcare Companies: Revvity (RVTY) and Candel Therapeutics (CADL) - The Globe and Mail
Portolan Capital Management LLC Trims Position in Candel Therapeutics, Inc. $CADL - MarketBeat
Responsive Playbooks and the CADL Inflection - Stock Traders Daily
Citigroup Cuts Candel Therapeutics (NASDAQ:CADL) Price Target to $22.00 - MarketBeat
Candel Therapeutics (NASDAQ:CADL) Earns "Buy" Rating from Canaccord Genuity Group - MarketBeat
H.C. Wainwright reiterates Candel Therapeutics stock rating at buy By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Candel Therapeutics stock rating at buy - Investing.com
Restrictive RTW Purchase Agreement Covenants Threaten Candel Therapeutics’ Financial Flexibility and Increase Default Risk - TipRanks
Small cap wrap: 374Water, Ideal Power, Northstar Gold, Candel Therapeutics… - Proactive financial news
Candel Therapeutics (NASDAQ:CADL) Issues Quarterly Earnings Results, Misses Expectations By $0.30 EPS - MarketBeat
Candel Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Candel Therapeutics strengthens balance sheet as lead cancer therapy advances - Yahoo Finance
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights - Bitget
Candel Therapeutics, Inc. announces financial results for the fourth quarter and full year of fiscal 2025, along with recent strategic updates. - Bitget
CADL: Pivotal trials and BLA submission planned for 2026, with strong financial runway into 2028 - TradingView
BRIEF-Candel Therapeutics Q4 Net Income USD -29.496 Million - TradingView
Funding extends Candel Therapeutics (NASDAQ: CADL) cash runway into early 2028 - Stock Titan
Tech Rally: Is Candel Therapeutics Inc stock suitable for long term investing2026 Momentum Check & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Candel Therapeutics (NASDAQ:CADL) Raised to Hold at Zacks Research - MarketBeat
Candel Therapeutics Presents New Data From Phase 3 Trial Of Aglatimagene Besadenovec In Localized Prostate Cancer - marketscreener.com
Candel Therapeutics Back On The Radar As Prostate And Lung Cancer Trial Catalysts Approach - RTTNews
Candel Therapeutics to present Phase 3 prostate cancer data at AUA 2026 - Proactive Investors
Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting - Bitget
Gainers Report: How Candel Therapeutics Inc. stock compares to market leadersWeekly Market Report & Growth Focused Investment Plans - Naître et grandir
Moving Averages: Will Candel Therapeutics Inc. stock outperform Nasdaq indexJuly 2025 Selloffs & Smart Allocation Stock Tips - Naître et grandir
Candel Therapeutics (CADL) Projected to Post Earnings on Thursday - MarketBeat
CADL SEC FilingsCandel Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Candel Therapeutics, Inc. showcases linoserpaturev immunotherapy progress in recurrent glioblastoma case - Traders Union
United StatesGoodwin Guides Candel Therapeutics On $100 Million Public Offering And $100 Millon Royalty Funding Agreement With RTW - Mondaq
CADL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Understanding the Setup: (CADL) and Scalable Risk - Stock Traders Daily
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Candel Therapeutics CEO to present progress on immunotherapies at TD Cowen Health Care Conference - Traders Union
CADL Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Hedge Fund and Insider Trading News: David Tepper, Steve Cohen, Ray Dalio, Brevan Howard, Millennium Management, Citadel Investment Group, Candel Therapeutics Inc (CADL), Meta Platforms Inc (META), and More - Insider Monkey
Candel Therapeutics Insider Bought Shares Worth $2,999,996, According to a Recent SEC Filing - marketscreener.com
Paul Manning buys Candel Therapeutics (CADL) shares worth $3m - Investing.com
Paul Manning buys Candel Therapeutics (CADL) shares worth $3m By Investing.com - Investing.com Australia
Candel Therapeutics (NASDAQ:CADL) Director Paul Manning Purchases 550,458 Shares - MarketBeat
Director Paul B. Manning adds 550,458 Candel (NASDAQ: CADL) shares via revocable trust - Stock Titan
Candel Therapeutics, Inc. (CADL) Stock Analysis: Unveiling a 259% Potential Upside in Biotech - DirectorsTalk Interviews
1.20%
0.06%
자본화:
|
볼륨(24시간):